title: Assessment of genetic markers and glioblastoma stem-like cells in activation of dendritic cells.
abstract: Glioblastoma (GBM) is the most common and aggressive intraparenchymal primary brain tumor in adults. The principal reasons for the poor outcomes of GBM are the high rates of recurrence and resistance to chemotherapy. The aim of this study was to determine the role of tailored cellular therapy for GBM with a poor prognosis and compare the activity of dendritic cells (DCs) that have encountered GBM cells. Detecting the correlations between methylation and expression of MGMT and PTEN genes and GBM cancer stem cells (CSCs) markers after co-cultures with a mononuclear cell cocktail are also aims for this study. Allogenic umbilical cord blood (UCB)-derived DCs were labeled with the CD11a and CD123 for immature DCs, and CD80 and CD11c for mature DCs. CD34, CD45, and CD56 cells were isolated from allogenic UCB for using in DCs maturation. GBM CSCs were detected with CD133/1 and CD111 antibodies after co-culture studies. DC activation was carried out via GBM cells including CD133 and CD111 cells and a mononuclear cells cocktail including CD34, CD45, and CD56 natural killer cells. Real-time PCR was performed to detect the expression and promoter methylation status of PTEN and MGMT genes. The expression of CSCs markers was found in all GBM cases, and a statistically significant correlation was found among them after co-culture studies. The most pronounced affinity of DCs to GBM cells was observed at dilutions between 1/4 and 1/256 in co-cultures. There was a statistically significant correlation between cellularity and granularity ratios for CD123 and CD11c. PTEN and MGMT gene expression and methylation values were evaluated with respect to CSCs expression and no statistical significance was found. Activation of DCs might associate with CSCs and the mononuclear cells cocktail including CD34, CD45, and CD56 cells which were obtained from allogenic UCB.
authors.affiliation: Cancer Research Center, Ege University, Bornova, 35100, Izmir, Turkey.
authors.forename: Aysel
authors.initials: A
authors.lastname: Yurtsever
authors.forename: Ayfer
authors.initials: A
authors.lastname: Haydaroglu
authors.forename: Cigir
authors.initials: C
authors.lastname: Biray Avci
authors.forename: Cumhur
authors.initials: C
authors.lastname: Gunduz
authors.forename: Nezih
authors.initials: N
authors.lastname: Oktar
authors.forename: Tayfun
authors.initials: T
authors.lastname: Dalbasti
authors.forename: Hasan Onur
authors.initials: HO
authors.lastname: Caglar
authors.forename: Rukset
authors.initials: R
authors.lastname: Attar
authors.forename: Gul
authors.initials: G
authors.lastname: Kitapcioglu
mesh_terms: D015703:Antigens, CD; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D064987:Cell- and Tissue-Based Therapy; D018920:Coculture Techniques; D015254:DNA Modification Methylases / Q000378:metabolism; D045643:DNA Repair Enzymes / Q000378:metabolism; D003713:Dendritic Cells / Q000166:cytology* / Q000473:pathology; D005312:Fetal Blood / Q000166:cytology; D015972:Gene Expression Regulation, Neoplastic; D005819:Genetic Markers / Q000235:genetics*; D005909:Glioblastoma / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008745:Methylation; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000378:metabolism; D011379:Prognosis; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D005819:Genetic Markers; D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D045643:DNA Repair Enzymes